News
Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’
The TRANSITION study has provided evidence on the safety and efficacy of administering sacubitril/valsartan to patients after acute decompensation of chronic heart failure with reduced ejection fraction of the left ventricle (HFrEF). A recent sub-analysis of its results suggested that not only patients with a long-known diagnosis but also those with newly diagnosed HFrEF could benefit from the treatment if the possibility of its prescription in this indication arises.
Could candesartan counteract adverse intestinal changes induced by hypertension?
An experimental study published last year was the first to show that administration of candesartan…
Pharmacokinetics and Safety Profile of Bilastine in Patients Aged 6–11 Years – Findings from Post-hoc Analysis of Studies
The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic…
A Brief History of Deep Vein Thrombosis Treatment – From Antiquity to the Present
Deep vein thrombosis is among the common diseases that have accompanied humanity since its…
Current Recommendations of the American Society of Hematology for the Prevention of Thromboembolic Disease and Duration of Prophylaxis in Patients Undergoing Major Surgery
At the end of 2019, new recommendations were published by the American Society of Hematology (ASH)…
More Patients Will Now Have Access to Incontinence Aids
Since December of last year, new rules have been in effect for the prescription of medical aids…
Assessment of Infection Risk in Patients with Multiple Sclerosis Treated with Various DMDs
Although the increased risk of infections with some disease-modifying drugs (DMDs) is known, we…
Effects of Telmisartan on Vascular Endothelial Functions, Inflammation Parameters, and Insulin Resistance in Patients with CHD and DM
Patients with coronary heart disease (CHD) and diabetes mellitus (DM) often have dysfunctional…
Metabolic Effect of Telmisartan and Candesartan in Kidney Transplant Patients
Increasing cardiovascular risk from complex causes warrants a comprehensive intervention. A…
Favorable effect of linagliptin on renal endothelial functions in patients with type 2 diabetes mellitus
Diabetic nephropathy is the cause of up to 50% of cases of end-stage chronic kidney disease. The main...
Conferences
News from the world of medicine
All conferences
Popular this week
- Intermittent Fasting May Carry Significant Health Risks
- Good, Bad, or Ugly? What's the Deal with Eggs?
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Modern approaches enhancing the efficiency of antibiotic therapy in hospital practice
- Patient blood management – past, present and future